Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836352 · ClinicalTrials.gov registry record · Phase 2
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
A Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Active
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT03836352 is a Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is active but no longer recruiting, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 184 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03836352, a Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- OTHER DPX-Survivac
Study Locations (20)
Ontario
- William Osler Health System - Brampton
- Juravinski Cancer Center - Hamilton
- Southlake Regional Health Center - Newmarket
- The Ottawa Hospital - Ottawa
- Sunnybrook Research Institute - Toronto
Florida
- Boca Raton Regional Hospital, Lynn Cancer Institute - Boca Raton
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
- Comprehensive Hematology and Oncology - St. Petersburg
New York
- NYU Winthrop Hospital - Mineola
- Montefiore Medical Center - The Bronx
Texas
- Mary Crowley Cancer Research Center - Dallas
- MD Anderson - Houston
Arizona
- The University of Arizona Cancer Center - Tucson
California
- Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center - Los Angeles
Georgia
- Winship Cancer Institute: The Emory Clinic - Atlanta
Kentucky
- James Brown Graham Cancer Center:University of Louisville Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836352
The ClinicalTrials.gov registry entry for NCT03836352 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The listed sponsor is ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03836352 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Ontario, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03836352 about?
NCT03836352 is a clinical study titled "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors". This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
What is the current status of trial NCT03836352?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2018-12-21. Estimated completion is 2023-12-31.
What conditions does trial NCT03836352 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Bladder Cancer, Hepatocellular Carcinoma, Microsatellite Instability High.
What interventions are being tested in trial NCT03836352?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), DPX-Survivac (OTHER).
Who is sponsoring clinical trial NCT03836352?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03836352 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.